ProPhase Labs, Inc. (PRPH)
Company Info
US74345W1080
74345W108
Jan 16, 1997
Highlights
$15.16M
-$2.33
$652.00K
$1.21M
-$25.82M
$0.22 - $5.22
$13.80
0.59%
0.31
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
ProPhase Labs, Inc. (PRPH) returned -51.79% year-to-date (YTD) and -92.91% over the past 12 months. Over the past 10 years, PRPH returned -4.42% annually, underperforming the S&P 500 benchmark at 10.85%.
PRPH
-51.79%
7.48%
-52.60%
-92.91%
-64.95%
-23.52%
-4.42%
^GSPC (Benchmark)
0.51%
6.15%
-2.00%
12.92%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of PRPH, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -65.22% | 70.45% | -9.92% | -13.93% | 4.89% | -51.79% | |||||||
| 2024 | 7.30% | -7.84% | 44.74% | -28.75% | 11.71% | -18.83% | -26.79% | -12.09% | -10.04% | -5.37% | -66.29% | -1.92% | -83.25% |
| 2023 | -15.06% | -10.64% | 4.24% | -1.57% | 26.53% | -23.50% | 0.28% | -41.21% | 2.10% | 0.46% | 15.49% | -10.85% | -53.06% |
| 2022 | 0.91% | -8.49% | 10.76% | 6.00% | 26.45% | 40.11% | -18.45% | 17.12% | -6.85% | 6.83% | -13.94% | -7.14% | 45.87% |
| 2021 | 10.24% | -24.31% | -3.46% | -27.92% | -5.49% | 29.17% | 15.48% | -25.14% | -2.98% | 13.27% | 6.62% | 14.17% | -18.04% |
| 2020 | 0.51% | -1.90% | -2.70% | -11.73% | -4.69% | -9.50% | 18.84% | 60.82% | 25.82% | 109.25% | 44.75% | -12.40% | 366.00% |
| 2019 | 4.54% | -1.31% | -0.00% | -0.33% | -0.00% | -28.33% | -5.58% | -1.24% | -3.74% | -3.00% | 17.52% | 1.02% | -23.83% |
| 2018 | 14.28% | -5.24% | 25.96% | -3.26% | 49.90% | 28.85% | -8.61% | 2.02% | -0.99% | -0.33% | 1.34% | 3.96% | 147.03% |
| 2017 | -5.01% | 7.37% | 11.27% | -11.01% | -4.46% | 8.30% | 0.00% | 5.26% | -2.73% | 1.61% | 3.48% | -3.56% | 8.49% |
| 2016 | -18.66% | -1.65% | 16.68% | -7.14% | 12.76% | -10.64% | 18.32% | 18.06% | 7.66% | 1.46% | 1.05% | -0.98% | 33.34% |
| 2015 | 8.90% | -12.57% | -5.76% | -1.53% | 7.77% | -2.89% | 11.11% | 1.34% | 3.95% | -3.17% | -5.22% | 3.44% | 2.73% |
| 2014 | 28.57% | -2.90% | -0.49% | -1.00% | -3.53% | -11.53% | -8.28% | -3.87% | -6.04% | -0.71% | 2.87% | 2.10% | -9.32% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of PRPH is 8, meaning it’s performing worse than 92% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for ProPhase Labs, Inc. (PRPH) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
ProPhase Labs, Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend | $0.00 | $0.00 | $0.00 | $0.60 | $0.30 | $0.00 | $0.50 | $2.00 |
Dividend yield | 0.00% | 0.00% | 0.00% | 6.23% | 4.18% | 0.00% | 25.38% | 63.49% |
Monthly Dividends
The table displays the monthly dividend distributions for ProPhase Labs, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.30 | $0.00 | $0.00 | $0.30 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.60 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.30 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.30 |
| 2020 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2019 | $0.25 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.25 | $0.50 |
| 2018 | $1.00 | $1.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.00 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the ProPhase Labs, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ProPhase Labs, Inc. was 98.39%, occurring on Feb 4, 2025. The portfolio has not yet recovered.
The current ProPhase Labs, Inc. drawdown is 97.52%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.39% | Jul 12, 2022 | 645 | Feb 4, 2025 | — | — | — |
| -97.06% | Oct 8, 1997 | 3613 | May 10, 2012 | 2105 | Dec 1, 2020 | 5718 |
| -71.19% | Jan 19, 2021 | 64 | Apr 20, 2021 | 306 | Jul 7, 2022 | 370 |
| -43.61% | Feb 20, 1997 | 49 | Apr 30, 1997 | 47 | Jul 8, 1997 | 96 |
| -26.94% | Jan 24, 1997 | 5 | Jan 30, 1997 | 13 | Feb 19, 1997 | 18 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ProPhase Labs, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of ProPhase Labs, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 26.2% positive surprise.
Valuation
The Valuation section provides an overview of how ProPhase Labs, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for PRPH compared to other companies in the Drug Manufacturers - Specialty & Generic industry. PRPH currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PRPH relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, PRPH has a P/S ratio of 2.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PRPH in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, PRPH has a P/B value of 1.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |